MedTrace Logo

The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D

NCT03246451 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2018-07-09

No results posted yet for this study

Summary

Delineation of the role of glucagon-like peptide-1 receptor signalling in the glucose-lowering effect of metformin during meal ingestion in patients with type 2 diabetes.

Conditions

  • Glucose Metabolism Disorders

Interventions

DRUG

Placebo Oral Tablet

2-4 tablets in 14 days

DRUG

Metformin

1000-2000 mg in 14 days

DRUG

Saline

9 mg/ml saline infusion during experimental days

DRUG

Exendin (9-39)

Infusion of GLP-1 receptor antagonist used as a tool during experimental days

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Filip K Knop, MD, PhD · UHGentofte, Center for Diabetes Research

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2017-12-10
Completion
2017-12-10

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03246451 on ClinicalTrials.gov